Researchers from Sutro Biopharma Inc. presented data on dual-payload antibody-drug conjugates (ADCs) engineered to overcome drug resistance, demonstrating enhanced cytotoxicity and potential efficacy in resistant cancer models.
Sutro Biopharma Inc. has outlined its next-generation antibody-drug conjugate (ADC) pipeline following recent IND clearance and initiation of phase I for its tissue factor-targeting ADC, STRO-004.
Researchers from the University of Oslo and Oncoinvent ASA present a new PTK7-targeted α therapy using a lead-212 (212Pb)-labeled antibody, potentially offering a novel approach for treating PTK7-expressing malignancies, and its assessment in a preclinical study.
